Tranzyme Pharma (NASDAQ: TZYM), based in Durham, NC, is a clinical stage biopharmaceutical company developing novel, small molecule therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. Their current pipeline targets two key recpetors, ghrelin and motilin, which regulate GI motility, appetite, and metabolism. TZP-102, an oral ghrelin agonist, recently completed enrollment for an ongoing Phase 2b trial. Tranzyme is also developing a motilin antagonist, TZP-201 for the treatment of various forms of moderate-to-severe diarrhea, and a ghrelin antogonist, TZP-301, for the treatment of obesity and other metabolic diseases.
For more information visit: http://www.tranzyme.com/